Skip to main content
. 2018 Jul 20;1(3):e180826. doi: 10.1001/jamanetworkopen.2018.0826

Table 1. Baseline Characteristics of the Study Cohort Stratified by Osteoporosis Medication Exposure.

Variable No. (%) Standardized Difference
Initiators (n = 2116) Nonusers (n = 16 569)
Demographic characteristics
Age, mean (SD), y 78 (10.4) 80 (10.7) −13.7
Male 416 (19.7) 5756 (34.7) −34.4
Fracture risk factors
Osteoporosis 261 (12.3) 1119 (6.8) 19.1
Prior vertebral fracture 61 (2.9) 503 (3.0) −0.9
Prior humerus fracture 69 (3.3) 515 (3.1) 0.9
Prior radius or ulna fracture 53 (2.5) 472 (2.8) −2.1
Prior pelvic fracture 99 (4.7) 941 (5.7) −4.5
Any other prior fracture 656 (31.0) 5478 (33.1) −4.4
Bone mineral density procedure ordered 66 (3.1) 259 (1.6) 10.3
Medication use potentially affecting fracture risk
Anticonvulsants 223 (10.5) 1843 (11.1) −1.9
Benzodiazepines 429 (20.3) 3162 (19.1) 3
Selective serotonin reuptake inhibitors 482 (22.8) 3654 (22.1) 1.7
β-Blockers 675 (31.9) 5045 (30.4) 3.1
Proton pump inhibitors 491 (23.2) 3796 (22.9) 0.7
Opioids 872 (41.2) 5780 (34.9) 13.1
Oral glucocorticoids 72 (3.4) 394 (2.4) 6.1
Comorbid conditions
Parkinson disease 64 (3.0) 586 (3.5) −2.9
Alzheimer disease 242 (11.4) 2985 (18.0) −18.6
Obesity 40 (1.9) 316 (1.9) −0.1
Diabetes 408 (19.3) 3621 (21.9) −6.4
Rheumatoid arthritis 66 (3.1) 330 (2.0) 7.1
Falls, syncope, or gait disturbances 615 (29.1) 5592 (33.7) −10.1
Health care use factors, mean (SD), No.
Distinct medications 4 (3.7) 4 (3.8) 6.3
Emergency department visits 1 (0.8) 1 (1.0) −11.3
Hospitalizations 1 (0.4) 1 (0.5) −8.2
Office visits 5 (4.3) 4 (4.3) 5.6